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We have assessed the numbers of potentially deleterious variants in the genomes of apparently healthy humans by using (1) low-
coverage whole-genome sequence data from 179 individuals in the 1000 Genomes Pilot Project and (2) current predictions and data-
bases of deleterious variants. Each individual carried 281–515 missense substitutions, 40–85 of which were homozygous, predicted to
be highly damaging. They also carried 40–110 variants classified by the Human Gene Mutation Database (HGMD) as disease-causing
mutations (DMs), 3–24 variants in the homozygous state, and many polymorphisms putatively associated with disease. Whereas
many of these DMs are likely to represent disease-allele-annotation errors, between 0 and 8 DMs (0–1 homozygous) per individual
are predicted to be highly damaging, and some of them provide information of medical relevance. These analyses emphasize the
need for improved annotation of disease alleles both in mutation databases and in the primary literature; some HGMD mutation
data have been recategorized on the basis of the present findings, an iterative process that is both necessary and ongoing. Our estimates
of deleterious-allele numbers are likely to be subject to both overcounting and undercounting. However, our current bestmean estimates
of ~400 damaging variants and ~2 bona fide disease mutations per individual are likely to increase rather than decrease as sequencing
studies ascertain rare variants more effectively and as additional disease alleles are discovered.Introduction
Genetic variation contributes to human ill health. Hence,
identifying the variants that underlie the disease pheno-
types (such variants are referred to here as ‘‘disease vari-
ants’’ or ‘‘disease alleles’’) of affected individuals has been
an important goal of medical geneticists for decades. The
comprehensive catalogs of both high-penetrance variants
underlying Mendelian disorders (Online Mendelian Inher-
itance in Man and Human Gene Mutation database
[HGMD])1 and low-penetrance variants contributing to
complex disorders (National Human Genome Research
Institute [NHGRI] Catalog of Published Genome-wide
Association Studies) attest to the progress made to date.
In parallel, researchers have made attempts to predict the
functional consequences of DNA variants, particularly
missense variants (leading to amino acid substitutions) in
protein-coding genes,2,3 with the aim of identifying poten-
tially damaging mutations independently of a known
disease association. Apparently healthy individuals can,
for a number of reasons, carry many disadvantageous vari-
ants without showing any obvious ill effects: (1) they
might carry a single disease allele for a severe high-pene-
trance recessive disorder that requires two alleles to mani-
fest the disease phenotype, (2) the disorder might be late in
onset or require additional genetic and/or environmental
factors for expression (reduced penetrance), (3) or the clin-
ical phenotypemight bemild and classified as lying within
the range of normal healthy variation. Indeed, many1The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK; 2In
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perceptible impact on health and hence can be tolerated.
In addition, available catalogs of disease alleles are invari-
ably imperfect: not only are they far from complete,
because most variants in the human population are very
rare and disease-allele discovery has barely begun in
many populations, but, more confusingly, they can also
contain entries that have been erroneously included as
disease variants. Indeed, as many as 27% of database
entries were judged to be potentially unreliable in one
recent assessment.4 It is clearly important that such uncer-
tain records be identified in order that genomic sequences
can be reliably interpreted in a medical context, and this
will be increasingly relevant as we enter a new era of
personalized genomics.5
Assessing the magnitude of the ‘‘genetic burden’’
imposed by harmful alleles on the general population
has been an aim of medical and population geneticists
since the first half of the 20th century. In early theoretical
treatments, Muller estimated that ‘‘the average individual
is probably heterozygous for at least [eight] genes, and
possibly for scores, each of which produces a significant
but usually slight detrimental effect,’’6 whereas Morton
et al. calculated from a consideration of consanguineous
marriages that ‘‘the average person carries heterozygously
the equivalent of [three to five] recessive lethals.’’7 Subse-
quently, it has been argued that individuals could carry
as many as 100 lethal equivalents,8 and a recent consider-
ation of likely numbers of disease alleles per individual institute of Medical Genetics, School of Medicine, Cardiff University, Heath
y of Human Genetics.
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the general population resulted in a ‘‘best guess’’ of 31.9
Large-scale sequencing studies have suggested that the
numbers of variants encoding amino acid substitutions
predicted to be damaging to the protein in a sample of
10,150 genes were 426 heterozygotes (range ¼ 340–534)
and 92 (range ¼ 77–113) homozygotes per individual;10
numbers over the entire genome might be twice these.
Other studies also support the view that many missense
variants are likely to be damaging.11–13 Furthermore, the
proportion of damaging substitutions appeared to be
higher in individuals of European ancestry than in those
of African ancestry.10 Although these studies focused on
coding variation, noncoding positions in the human
genome can be equally evolutionarily constrained; varia-
tion at such sites might provide the majority of functional
variation in each individual9 but is currently not as easily
studied.14,15 In an alternative approach, a survey of 437
genes known to underlie recessive Mendelian diseases
revealed 2.8 (range ¼ 0–7) severe mutations per indi-
vidual.4 It is difficult to estimate the numbers per complete
genome, but they would clearly be higher. Similarly,
another survey of 417 recessive Mendelian variants discov-
ered ~0.4 recessive lethals per individual and also that
~0.3% of the study population was homozygous or
compound heterozygous for a severe condition,16 and
a study of the Hutterite population showed ~1.1 recessive
disease mutations per individual.17 Personal genome
sequences have not only provided estimates of the number
of disease variants (e.g., 19) carried by each subject18 but
have also given us a glimpse of the likely complexity of
the functional interpretation of such data.19 Taken
together, theoretical and experimental studies suggest
that individuals typically carry hundreds of mildly disad-
vantageous variants and several severe disease alleles.
Such findings emphasize the difficulties of interpreting
variant function and hence point to the need for addi-
tional information.
Advances in sequencing technology now allow genetic
variation to be discovered efficiently throughout most of
the genome in population samples.20 In a pilot study for
the 1000 Genomes Project, we reported the numbers of
disease alleles, defined by reference to the disease-causing
mutations (DMs) listed in HGMD,1 in population samples
of African, European, and East Asian origin. These
numbers were surprisingly high, for example, 57–80
disease alleles per individual (interquartile range) in
a sample of 179 participants. Moreover, further examina-
tion of these numbers showed that 191 disease alleles
were present in the homozygous state in at least one indi-
vidual and hence were not present simply because their
effects were masked by a normal allele. Although little
phenotypic information other than sex, ethnicity, place
of origin, and relationship to other participants is available
for the 1000 Genome Project donors, the project’s ethical
process requires that sample donors be nonvulnerable
adults who are competent to consent to participation in
the project. It seems unlikely that they will have sufferedThe American Joufrom overt genetic disease at the time of sampling. Instead,
it seems important to seek some other explanation for the
high numbers of DMs. For example, the penetrance of the
disease alleles might be lower than previously realized.
Most past studies have identified a genotype given a disease
phenotype; this is very different from identifying a pheno-
type given a (disease-associated) genotype. Alternatively,
these alleles might not actually be pathogenic at all—
theymight have been erroneously reported and then inap-
propriately entered into the mutation database. Finally,
they might represent sequencing errors in the 1000
Genomes Project data.21 These considerations prompted
us both to re-examine the disease-allele findings of the
1000 Genomes Pilot Project and to extend the analyses
to other categories of potentially harmful variants.
For this follow-up study, we adopted two different
approaches. We evaluated the predicted properties of
missense variants in the data set irrespective of whether
they are currently annotated (in the HGMD) as disease
alleles. In addition, we expanded the sample of disease
alleles (defined as those present in the HGMD) to include
other categories. HGMD entries are currently classified in
two distinct ways: first by function (DMs, disease-associ-
ated polymorphisms [DPs], DPs with additional support-
ing functional evidence [DFPs], or in vitro or in vivo
functional polymorphisms [FPs]) and second by variant
type (base substitutions [further subdivided into missense,
nonsense, regulatory, and essential splice variants],
microindels, microdeletions, microinsertions, and some
additional categories not employed here). We therefore
identified the overlap of each of these categories (by
combining microindels, microdeletions, and microinser-
tions into one category, henceforward referred to as ‘‘in-
dels’’) with the 1000 Genomes Pilot data and concentrated
on the Low-Coverage Pilot because the Exon Pilot identi-
fied fewer overlaps and because these have already been re-
analyzed in some detail.22 We then applied a number of
different approaches to evaluate the likely functional
impact of these overlapping variants and hence the
apparent ‘‘genetic burden’’ experienced by the human
population.Material and Methods
Data Sources
1000 Genomes Low-Coverage Pilot data20 were downloaded from
the 1000 Genomes Project website. This data set is based on the
NCBI human reference genome build 36, which is used here as
well. HGMD data were obtained from HGMD Professional release
2009.4. Overlaps were identified as variants sharing the same
genomic coordinate and, for base substitutions, the same nucleo-
tide. The number of overlapping DMs was corrected from 57820 to
577 (Table 1). Indel overlaps were those present in both the Low-
Coverage Pilot data and the ‘‘small insertion,’’ ‘‘small deletion,’’
and ‘‘small indel’’ classes of HGMD data. We initially allowed 5
10 bp in genomic coordinate and subsequently manually exam-
ined the indels to assess whether or not the variant structuresrnal of Human Genetics 91, 1022–1032, December 7, 2012 1023
Table 1. Summary of HGMD Data
Variant Types
DM FP DFP DP
HGMD
Total Overlap
Homozygous
Overlap
HGMD
Total Overlap
Homozygous
Overlap
HGMD
Total Overlap
Homozygous
Overlap
HGMD
Total Overlap
Homozygous
Overlap
Missense and
nonsense SNPs
50,361 577 191 1,210 313 157 273 208 168 1,068 767 633
Regulatory
SNPs
626 44 19 341 245 208 378 340 317 338 294 271
Essential
splice sites
5,830 7 0 40 3 1 2 2 2 7 3 1
Other
splice sites
2,229 95 36 62 37 31 39 39 36 157 141 124
Small indels 1,319 0 0 14 0 0 4 0 0 4 0 0
Small
deletions
14,411 5 3 70 7 6 4 1 1 21 4 3
Small
insertions
5,934 1 0 29 0 0 5 0 0 7 1 1
‘‘HGMD Total’’ represents variants found in the HGMD data set. ‘‘Overlap’’ represents variants found in both the HGMD and the 1000 Genomes Low-Coverage
Pilot data sets. ‘‘Homozygous overlap’’ represents those variants found in both data sets and observed in the homozygous state in one or more individuals. The
following abbreviations are used: DM, disease-causing mutation (pathological mutation reported to be disease causing in the report entered into HGMD); FP,
in vitro or in vivo functional polymorphism (polymorphism reported to affect the structure, function, or expression of the gene [or gene product] but with no
disease association reported as yet); DFP, disease-associated polymorphism with additional supporting functional evidence (polymorphism reported to be in
significant association [p < 0.05] with disease and that has evidence of being of direct functional importance [e.g., as a consequence of altered expression,
mRNA studies, etc.]); and DP, disease-associated polymorphism (polymorphism reported to be in significant association [p < 0.05] with a disease or phenotype
and that is assumed to be functional [e.g., as a consequence of location, evolutionary conservation, replication studies, etc], although there might not yet be any
direct evidence [e.g., from an expression study] of a functional effect).were the same. The ancestral states used were those annotated in
the 1000 Genomes genotype (.vcf) files; the few sites lacking
ancestral annotation were excluded from analyses requiring this
information.
HGMD DM Genotype Validation
Two approaches were used for validation of the HGMD DM geno-
type calls. Twenty of the pilot samples were sequenced to high
coverage by Complete Genomics with independent tech-
nology.23 In these overlapping samples, 318 of the 577 DMdisease
alleles were called by the 1000 Genomes Project. Among these, the
disease allele was also called by Complete Genomics at 316 sites,
although in a different individual in one case. These 316 DM
site calls were regarded as validated, and two were not validated,
giving a site validation rate of 99.4%. Genotype concordance
was 97.9% (6,224/6,360, Table S1, available online) and 100%
among the DM sites that were variable and invariable, respectively,
in these 20 individuals. In addition, five sites, including all HGMD
DMs in the filtered list found as homozygotes and not already vali-
dated, were tested by capillary sequencing. All were confirmed as
being homozygous for the disease allele (Figure S1).
Statistical Analyses
Derived allele-frequency (DAF) spectra were compared with
a Mann-Whitney U test, and the overrepresentation or underrep-
resentation of the lowest frequency bin (0%–10%) was assessed
with a Chi-square test. The dependence of DAF on consensus dele-
teriousness (Condel) scores24 was analyzed with Spearman’s and
Kendall’s rank correlations.
Manual Curation of Variants
We sought further data on variants of interest in PubMed andGoo-
gle by using the dbSNP reference SNP ID number, gene name, or1024 The American Journal of Human Genetics 91, 1022–1032, Decedisorder name as a search term and by identifying publications
that cited the reference listed in the HGMD PubMed Unique Iden-
tifier field. Disease association was accepted when association with
disease in the original reference or an additional source was statis-
tically significant or when functional data, such as cell line or
model-organism studies, identified a relevant biological effect.
All of the overlapping indels and essential splice sites, as well as
an initial 20 missense DMs chosen randomly from the list of
577 and all 71 filtered DMs listed in Table 2 and Table S2, were as-
sessed in this way.
Functional Prediction of Missense-Variant Deleterious
Properties
Weused Ensembl (release 65)-computedmodifiedCondel scores,24
which combine PolyPhen-22 and SIFT3 scores. We established
Condel score R 0.99 as a cutoff for disease variants on the basis
of the discrimination between Condel scores for HGMD DMs that
do not overlap with the 1000 Genomes Project Pilot data set on
the one hand and 1000 Genomes Project variants that have a fre-
quency>10%andat least onehomozygote and thatdonotoverlap
with HGMD DMs on the other (Figure 1). The accuracy of the
Condel predictions has been estimated to be about 88%–90%.24Results
Characterization of Missense Variants in Low-
Coverage Pilot Sequences
The most readily recognized deleterious variants are those
that disrupt a protein-coding gene either by leading to loss
of function (e.g., nonsense or frameshift variants) or by
altering an amino acid. Because the former category has
been the subject of an independent follow-up study,25 wember 7, 2012
Table 2. Filtered Disease Variants either Causing Dominant Disease or Causing Recessive Disease and Observed in the Homozygous State
RefSeq
Accession
Number Disease (MIM Number) Inheritance Gene Chr Position
HGVS
cDNA
Mutation
Protein
Alteration
Total
Homozygotes
Total
Heterozygotes Comments
NM_000051.3 ataxia telangiectasia
(MIM 607585)
AR ATM 11 107,665,560 c.4258C>T p.Leu1420Phe 1 3 low-penetrance breast cancer
susceptibility allele
NM_206933.2 Usher syndrome type IIA
(MIM 276901)
AR USH2A 1 214,490,898 c.2137G>C p.Gly713Arg 3 22 literature is ambiguous;
probable complex pathogenicity;
neutral in YRI?
NM_015102.3 nephronophthisis 4
(MIM 606966)
AR NPHP4 1 5,862,830 c.2542C>T p.Arg848Trp 1 2 growth retardation; adult-onset
renal disease
NM_000529.2 Cushing syndrome
(MIM 607397)
AR MC2R 18 13,874,685 c.833T>G p.Phe278Cys 1 10 hormonal disorder; variable
sex-specific symptoms; variant is
functionally defective in vitro
NM_000443.3 low-phospholipid-associated
cholelithiasis (MIM 171060)
AR ABCB4 7 86,887,281 c.2363G>A p.Arg788Gln 2 9 adult onset
NM_000256.3 cardiomyopathy,
hypertrophic (MIM 115197)
AD MYBPC3 11 47,320,810 c.1519G>A p.Gly507Arg 0 2 late onset; incomplete penetrance
NM_139281.2 glaucoma, primary open
angle (MIM 609887)
AD WDR36 5 110,473,878 c.1586G>A p.Arg529Gln 0 1 adult onset; variant is functionally
defective in vitro
NM_000249.3 colorectal cancer,
nonpolyposis (MIM 609310)
AD MLH1 3 37,064,024 c.1742C>T p.Pro581Leu 0 1 adult onset; variant is functionally
defective in vitro
NM_144997.5 renal cell carcinoma
(MIM 144700)
AD FLCN 17 17,066,604 c.715C>T p.Arg239Cys 0 1 late onset
NM_000185.3 heparin cofactor 2
deficiency (MIM 612356)
AD SERPIND1 22 19,464,223 c.623G>A p.Arg208His 0 2 deficiency state; no overt disease;
risk factor for thrombophilia
NM_005577.2 Lp(a) deficiency
(MIM 152200)
AD LPA 6 160,926,067 c.4289þ1G>A essential
splice site
0 5 risk factor in heart disease;
late onset
See Table S2 for full details of these variants. The following abbreviations are used: chr, chromosome; AR, autosomal recessive; AD, autosomal dominant; and YRI, Yoruba in Ibadan, Nigeria.
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Figure 1. Condel-Score Distribution for
HGMD-Only DMs, Variants Only in the
1000 Genomes Low-Coverage Pilot, and
Overlap Variants
Shown are Condel scores for HGMD-
only DMs (blue), variants only in the
1000 Genomes Low-Coverage Pilot data
(yellow), and overlap variants (green).
Condel scores range from 0 (the amino
acid change is predicted to not damage
the protein) to 1 (the amino acid change
is predicted to damage the protein). The
top decile of Condel scores is further subdi-
vided in the panel on the right-hand side.have focused here mainly on missense variants, consid-
ering the eight validated loss-of-function variants overlap-
ping with HGMD only in the final filtered data set. We
counted the number of derived heterozygous and homozy-
gous missense variants carried by each individual in
the 1000 Genomes Low-Coverage Pilot data (Table 1 and
Table S3). This analysis differs slightly from the earlier
study,20 where nonreference allele numbers were reported.
Derived missense-allele numbers per individual ranged
from ~13,000 (range ¼ 12,253–13,868) for the YRI (Yoruba
in Ibadan, Nigeria) samples to ~12,000 (range ¼ 11,715–
12,439 for CEU [Utah residents with ancestry from
northern and western Europe from the CEPH collection]
and 11,197–12,352 for CHB [Han Chinese in Beijing,
China] þ JPT [Japanese in Tokyo, Japan]) for the European
and Asian samples, as expected from the known higher
level of genetic variation in African populations.26
We next classified these variants according to the extent
of their predicted damaging effect on the protein.24
Around 3% fell into themost damaging class with a Condel
score R 0.99, and some differences were evident between
populations: there were, per individual, 377 [324–468]
for YRI, 321 [281–375] for CEU, and 435 [342–515] for
CHB þ JPT). Homozygous variant numbers in this most
damaging class were considerably lower: 53 (40–70), 62
(53–75), and 70 (51–85), respectively, for the same three
populations. These numbers, corresponding to a few
hundred damaging missense variants per individual, are
in line with previous estimates,10 although they are some-
what lower here, probably because amore stringent predic-
tion of damaging effect was employed. We could not
confirm the previously reported higher proportion of
damaging variants in individuals of European ancestry
(2.7% in CEU vs. 2.9% in YRI), although we did find
a greater proportion in East Asians (3.7%). However, the
biological interpretation of this discrepancy is not straight-
forward because the differences between populations in
our data are confounded by differences in both read depth
and error rate between the populations.20
Characterization of HGMD Variants in Low-Coverage
Pilot Sequences
We identified a total of 2,630 HGMD entries that were
present in the 1000 Genomes Low-Coverage Pilot data1026 The American Journal of Human Genetics 91, 1022–1032, Dece(Table 1 and Table S4). These were very unevenly distrib-
uted between the different categories. Forty-two percent
of the combined polymorphism classes (DP þ DFP þ FP)
were represented, whereas only 0.9% of the DMs were
present (Figure 2A). A large difference might be expected
because those entries classified as polymorphisms have
small (perhaps negligible) effects on disease risk and
received the designation ‘‘polymorphism’’ largely because
of their estimatedR1% frequency, whereas DMs are detri-
mental and generally rare. Similarly, there were also large
differences between the different variant types; for
example, 55% of the regulatory SNPs were present,
whereas only 0.08% of the combined ‘‘indel’’ classes were
(Figure 2B). These differences partly reflect the incomplete
discovery of indels in the 1000Genomes data, but there are
also differences within the SNP class. SNP types other than
regulatory SNPs are less frequently represented: 2.6% of
missense and nonsense SNPs, 0.2% of essential splice
SNPs, and 10% of nonessential splice SNPs. Frequency
differences between the SNP types are likely to reflect their
differential functional impacts.
In addition to the simple presence or absence of HGMD
variants in the Low-Coverage Pilot data, their frequency in
the population is likely to be informative. This can usefully
be summarized as a derived allele-frequency spectrum and
assessed by comparison with a variant class assumed to be
approximately neutral, such as synonymous SNPs, which
avoids interpretation biases as a result of the frequency-
dependent ascertainment bias inherent in low-coverage
sequencing. As reported by the Pilot Project,20 the spec-
trum for nonsynonymous SNPs is skewed more toward
lower frequencies than is that for synonymous SNPs in
all populations, reflecting their tendency to be slightly
deleterious (Figure 3). Of the HGMD overlap SNPs, all of
the polymorphism classes were skewed toward higher
frequencies, probably as a consequence of their ascertain-
ment as ‘‘polymorphisms;’’ however, the DMs were skewed
toward lower frequencies, consistent with their presumed
deleterious nature. Most of these differences were highly
significant (Figure 3; Table S3). This skewwasmost extreme
in the CEU samples, perhaps as a result of the better ascer-
tainment of low-frequency variants in this population
and/or a European publication bias influencing entry
into HGMD.mber 7, 2012
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Figure 2. Representation of HGMD Variant Classes in the 1000
Genomes Low-Coverage Pilot
(A) HGMD variants subdivided by functional category. The
following abbreviations are used: DM, disease-causing mutation;
FPs, in vitro or in vivo functional polymorphism; DFP, disease-
associated polymorphism with additional supporting functional
evidence; and DP, disease-associated polymorphism.
(B) HGMD variants subdivided by variant type. The first four types
are all SNPs.
The American JouAs a consequence of these differences in frequency, the
numbers of homozygous variants per individual differ
greatly between classes. They are generally high for the
polymorphism classes (Table 1), but the DMmissense vari-
ants still show an average of 15 (9–24), 10 (5–17), and 11
(3–22) for the YRI, CEU, and CHB þ JPT samples, respec-
tively. In addition, small numbers of disease-causing essen-
tial splice-site SNPs and indels were noted (Table 1).
Overall, the proportion of DP, DFP, and FP entries found
in the Low-Coverage Pilot data, as well as their allele-
frequency spectra, can be understood in terms of the
consequences of their relatively mild phenotypic effects
and ascertainment. However, although the low proportion
and skewed allele-frequency spectra of DMs are consistent
with, and indicative of, their expected deleterious proper-
ties, these variants are still surprisingly numerous and
frequent, both as heterozygotes and homozygotes. Valida-
tion rates of these specific variants were high, both for sites
(>99%) and for individual genotypes (~98%), so these
numbers are unlikely to reflect genotyping errors (Table
S1). We therefore investigated their disease implications
in more detail.
Refinement of HGMD DMs Present in Low-Coverage
Pilot Sequences
We next adopted two approaches to further assess the
overlapping DMs. First, we undertook manual recuration
of a sample to determine whether there was any addi-
tional published evidence for or against their pathoge-
nicity. Manual recuration was applied to all the disease-
causing ‘‘indels’’ and essential splice-site SNPs, as well as
to a proportion of the missense variants. Among the five
indels in this class, one (and 0/14 in the polymorphism
classes), a single-base deletion (c.50delT in PRF1 [MIM
170280; RefSeq accession number NM_001083116.1],
associated with the severe disease familial haemophago-
cytic lymphohistiocytosis) found in the heterozygous
state in a single YRI sample, was judged likely to be caus-
ative (entry CD993068 in the supplemental data sheet).
Of the seven essential splice-site SNPs, all were considered
likely to be causative, although they were associated with
mild phenotypes in four cases and with a moderate
phenotype, deafness, in a fifth case. In all seven, the
disease allele was observed only in the heterozygous state
in one to ten individuals. Among the missense DMs, we
found known pathological variants, such as HBB (MIM
603903; RefSeq NM_000518.4) c.20A>T (p.Glu7Val),
which leads to increased resistance to malaria in heterozy-
gotes but to sickle cell disease in homozygotes27 (there
were 12 heterozygotes and 1 homozygote in YRI, but
0 in CEU or CHB þ JPT). In addition, we found variants
exemplified by USH2A (MIM 276901; RefSeq
NM_206933.2) c.2138G>C (p.Gly713Arg), reported as
being causal for Usher syndrome type 2,28 a recessive
disorder characterized by combined deafness and blind-
ness and found in the homozygous state in three YRI
samples, despite the fact that it represents a phenotypernal of Human Genetics 91, 1022–1032, December 7, 2012 1027
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Figure 3. Derived Allele-Frequency
Spectra of Nonsynonymous and Synony-
mous Variants and HGMD SNPs in Three
1000 Genomes Low-Coverage Pilot
Samples
The following abbreviations are used:
NSV, nonsynonymous variant; SV, synon-
ymous variant; DM, disease-causing
mutation; FP, in vitro or in vivo functional
polymorphism; DFP, disease-associated
polymorphism with additional supporting
functional evidence; and DP, disease-
associated polymorphism.unlikely to be found among the sample donors. In the
case of this mutation, a subsequent report concluded
that this variant was unlikely to be causal for the disease
given that it was found in 2/200 controls;29 this complex
variant is considered further in the Discussion. Thus,
manual curation revealed the presence of three variant
classes among the DMs: (1) plausible severe disease-
causing variants, (2) variants convincingly causative for
pathological conditions yet compatible with adult life,
and (3) probably incorrect disease-status assignments.
However, it also became apparent that little or no relevant
additional information was available for the majority of
variants examined, and therefore, alternative approaches
to reassessment are required.1028 The American Journal of Human Genetics 91, 1022–1032, December 7, 2012In a second approach, we used the
damage prediction, as measured by
the Condel score implemented in
Ensembl, to stratify all 577 missense
variants. Using a score of R 0.99 as
a filter, we found that 55 DMs were
predicted to be damaging. Compared
with the initial 577 variants, these
55 were present at a significantly
lower frequency in the population
(p ¼ 0.007, Mann-Whitney U test).
A smaller proportion was seen as
homozygotes, and the number per
individual was also much smaller
and ranged from 0 to 7, of which
0 or 1 were homozygotes (Table 1).
Thus, this filter served to greatly
reduce the number of probable
disease alleles per individual.
The 55 damaging missense
DMs, the eight validated nonsense
DMs, and the splice-site and single-
base-deletion DMs discussed above
(the filtered shortlist of disease
alleles), along with the outcome of
their recuration, are summarized in
Table 2, Table S2, and the supple-
mental data sheet. Compared with
the HGMD as a whole, this filtered
set did not include any significantlyoverrepresented disease categories, perhaps because the
small numbers of alleles provided low power for
identifying such effects (Figure S2). Of the 71 entries, re-
curation caused three to be reclassified as FPs, 22 to
be considered probably not pathogenic, and two to be
considered truncating variants, leaving 45 judged to
be pathogenic. Most of these cause recessive disorders
and were found only in heterozygotes; this class of
variant is expected to be present in the general popula-
tion. Two groups, however, were unexpected. Six DMs
cause dominant disorders, and five DMs cause recessive
disorders but were found in the homozygous state in
one or more individuals. These 11 variants are discussed
further below.
Discussion
The 1000 Genomes Project Pilot data, as the first available
population-scale whole-genome sequence data set, has
provided an opportunity for researchers to assess the issues
accompanying the interpretation of apparently harmful
genetic variants in the human population. These data
must, however, be interpreted in the light of some signifi-
cant limitations. False disease-allele genotype calls,
however, are very low. False-discovery rates in the project
as a whole were controlled to be <5%, so the variants re-
ported are mostly reliable. Further, the erroneous variant
calls are unlikely to correspond to real variants logged in
mutation databases. In support of this, validation experi-
ments confirmed that genotyping error contributes very
little (<2%) to the results presented in this study; the
particularly low error rate most likely reflects the above-
average quality of the read mapping to gene regions. Simi-
larly, somatic mutations in the cell lines sequenced by the
project are also unlikely to correspond to HGMD entries.
False-negative rates in the Low-Coverage Pilot data were,
however, substantial for rare variants and represent a limi-
tation of this data set. Discovery in the Low-Coverage Pilot
was near complete for variants of frequencyR 5% but was
only about 30% for variants of 1% frequency. Thus, disease
variants, which are generally rare in the population,22 tend
to be underrepresented. Consequently, the numbers in the
current study should be regarded as conservative lower
bounds to the actual numbers in the general population.
One clear conclusion from this and other studies4 is that
there is an urgent need to improve disease-allele annota-
tion. Of the 577 HGMD DMs present in the Low-Coverage
Pilot data set, >90% were not predicted to be severely
damaging to the protein. Such predictions have error
rates > 10%,24 but the fact that higher scores are strongly
associated with lower allele frequencies (Table S5 and
Figure S3) indicates that they are, on average, subject to
stronger negative selection and are thus enriched with
deleterious alleles. Protein damage does not, of course,
invariably give rise to disease; this is most strikingly illus-
trated by the finding that each individual carries ~100
severe loss-of-function variants, ~20 of which are in the
homozygous state, without manifesting any evidence of
overt genetic disease.25 Conversely, the well-known HBB
sickle cell allele is clearly disease causing but has a Condel
score of 0.956 and hence lies outside our severely
damaging category. Like many loss-of-function variants,
some of the homozygous DMs are deleterious on a purely
biochemical level and hence manifest as a presumed defi-
ciency state (e.g., c.280C>T [p.Arg94*] in MOK [formerly
RAGE1 (MIM 605762; RefSeq NM_014226.1)]; Table S2)
without causing any overt disease in the individual con-
cerned. Some homozygotes are population specific,
leading to the possibility that these alleles might well be
deleterious in one population, but not in another (e.g.,
c.598A>G [p.Met200Val] in DMC1 [MIM 602721; RefSeq
NM_007068.2]).30,31 In addition, several of the homozy-The American Jougotes occur in association with phenotypes that require
a specific environmental trigger (e.g., STOX1 variants and
preeclampsia predisposition).32,33 Such considerations
point to the complexities of the annotation process
required. Nevertheless, it seems probable that many of
the 191 DMs identified here in the homozygous state are
likely to represent disease-allele-annotation errors. Because
HGMD inclusion is largely made on the basis of publica-
tion in the peer-reviewed literature, we can infer that the
editorial criteria for accepting a given variant as disease
causing in the original literature need to be made more
stringent. We suggest, for example, that missense variants
found in one or a few disease cases and in zero out of a few
hundred controls should no longer automatically be
accepted as disease causing in the absence of additional
functional evidence, particularly because the availability
of data from the 1000 Genomes Project and other studies
now makes determining allele frequencies in many popu-
lations relatively easy. This should serve to reduce the
proportion of putatively pathological missense variants
that turn out to be spurious, albeit at the price of falsely
excluding some truly pathogenic variants.
Nevertheless, simply tightening the criteria for inclusion
in mutation databases would not address the relevant bio-
logical issue of reduced penetrance. One of the best charac-
terized examples of incomplete penetrance is provided
by the c.845G>A (p.Cys282Tyr) mutation in the hemo-
chromatosis-associated gene HFE (MIM 613609; RefSeq
NM_000410.3). p.Cys282Tyr homozygotes are found at
a frequency of approximately 1 in 200 people of northern
European origin.34,35 Available data suggest that 38%–50%
of p.Cys282Tyr homozygotes develop iron overload
and that 10%–25% develop some form of hemochroma-
tosis-associated morbidity. However, there appears to be a
sex-dependent effect: large studies that have specifically
assessed liver disease in newly diagnosed p.Cys282Tyr
homozygotes have shown that disease manifests in
24%–43% of males and 1%–14% of females.36 The extent
of clinically relevant reduced penetrance inmutation data-
bases remains poorly understood but is an issue that
urgently needs further consideration.
Our conclusions about the high frequency of spurious
reported disease alleles do not, of course, apply to the
vast majority of HGMD DM entries, which were not found
in the 1000 Genomes samples. A simple best estimate of
the number of questionable entries in HGMD would lie
between 191 (overlapping homozygous DMs) and 577
(total overlapping DMs), i.e., 0.4%–0.9% of the total
number of entries, and >99% of these would be bona
fide by this criterion. Nevertheless, investigators se-
quencing individuals (in a clinical context) or personal-
genomics participants in order to understand their genetic
disease status are likely to encounter many erroneous
disease alleles. What steps can be taken for facilitating
interpretation in such a situation? One approach that
might be considered would be to regard all variants
found in the 1000 Genomes Project samples as beingrnal of Human Genetics 91, 1022–1032, December 7, 2012 1029
noncausative for disease. This, however, would be overly
conservative because disease variants are to be expected
in such a population, and indeed, a number of compelling
dysfunctional variants are observed. An alternative
approach would be to flag variants according to their
frequency in the 1000 Genomes Project samples, their
presence in the homozygous state, and/or their predicted
damage as part of the HGMD entry so that investigators
can make an informed judgment about their medical
relevance. In the longer term, more comprehensively
annotated databases of pathological or disease-associated
variants will be required; in the meantime, however, we
believe that the type of iterative approach to variant valida-
tion advocated here is the most efficient and hence most
appropriate way to go about constructing a comprehensive
lexicon of DMs, loss-of-function alleles, and damaging but
nonpathogenic amino acid substitutions; this will be
essential if personalized genomics is to enter the realm of
routine clinical practice.
After applying all the criteria for identifying true disease
alleles available to us, we were left with a list of 45 filtered
candidates (Table 2 and Table S2). Of these, 34 were present
only in carriers and do not require further discussion here.
Among the remaining 11, the 6 linked to dominant disor-
ders can be understood because they either have late onset
(e.g., c.1519G>A [p. Gly507Arg] inMYBPC3 [MIM 115197;
RefSeq NM_000256.3]) or no overt disease phenotype
(e.g., c.623G>A [p.Arg208His] in SERPIND1 [MIM
612356; RefSeq NM_000185.3]). Similarly, the presence
of homozygotes for four of the five recessive disorders
can be explained by late onset and/or reduced penetrance.
Accounting for c.2138G>C (p.Gly713Arg) in USH2A (MIM
276901; RefSeq NM_206933.2) is the most difficult; this
variant is strongly predicted to be damaging to the protein
by multiple approaches, including in silico modeling and
in vitro laboratory analysis.37 Despite this, the variant is
evidently nonpathogenic in some populations, such as
the YRI, yet is regarded as pathogenic in other popula-
tions.4 One explanation for this apparent contradiction
could be that in the YRI population, the USH2A locus is
subject to copy-number variation38 that could either
reflect the nonessential nature of the locus in YRI or
provide functional complementation of the mutant gene.
Usher syndrome type IIA is a rare disease found primarily
in populations of European descent39,40 and might not
be found in the YRI population at all, lending support to
this postulate. However, this possibility needs to be
investigated in a future study. Such ambiguities could
perhaps be clarified by genotype-based recall for further
phenotypic analyses or further CNV evaluation of study
participants; these approaches are not applicable to the
fully anonymized 1000 Genomes Project participants but
could be informative in other studies.
Our findings are also relevant to discussions about ‘‘inci-
dental findings,’’ which are, in this context, the uninten-
tional discovery of information about the future disease
prospects of the participants.41 Particularly relevant are1030 The American Journal of Human Genetics 91, 1022–1032, Decethe dominant diseases, as well as the recessive diseases
for which homozygotes were found. In all, 19/179 (11%)
individuals were affected (Table 2 and Table S2). In most
of these, the primary explanation for the absence of disease
at the time of recruitment is likely to be the age of onset,
although penetrance is often variable as well, and some
phenotypes, such as loose anagen hair syndrome (caused
by c.1009G>A [p.Glu337Lys] in KRT75 [MIM 600628;
RefSeq NM_004693.2]; Table S2), might not even be re-
garded as ‘‘diseases.’’ Nevertheless, several participants
might later develop a genetic disease. In this situation,
the participants might benefit from advice about risks to
avoid or monitoring as they age. 1000 Genomes Project
participants cannot be recontacted, but our findings
suggest that incidental findings relevant to health and
well-being might be detected in ~11% of subjects
sequenced; this number is likely to be an underestimate
because of our incomplete discovery of rare variants.
It is now abundantly clear that the number of functional
genes in the human genome varies between individuals,
perhaps by up to 10%, because of large-scale duplications
and deletions,42,43 small loss-of-function mutations,25,44
damaging missense substitutions,11,12and other forms of
genetic variation. It is also clear that much of this variation
has, at most, minor consequences for health. Nevertheless,
it is noteworthy that DMs, loss-of-function alleles, and
damaging amino acid substitutions (Table S5) as classes
are rarer in the population than variants that are approxi-
mately neutral, indicating that they are disadvantageous
and subject to purifying selection on an evolutionary time-
scale. They thus contribute to the ‘‘genetic burden’’ in the
general population. From the 1000 Genomes Pilot data, we
now see that an average individual typically carries ~60
missense variants that severely damage protein structure
and ~100 loss-of-function variants.25 These numbers are
probably biased upward in the sense that not all damaged
or inactivated protein-coding genes are harmful to health.
However, they are also certainly biased downward not only
because the use of a Condel-score cutoff of 0.99 is arbitrary,
and many variants with lower scores are likely to be delete-
rious to health, but also because the contribution of indels
and regulatory variants to these categories is likely to have
been seriously underestimated. Similarly, the observation
of 2.0 (range ¼ 0–7) filtered DMs per individual is affected
by a likely residue of noncausative variants that are not
removed by our filtering scheme but is also far from
complete because many disease-causing mutations still
remain to be discovered and entered into HGMD.9 There-
fore, giving a definitive estimate of the number of either
deleterious or disease-causing variants per individual is
impossible at this stage. We nevertheless speculate that as
our understanding improves, the effect of removing
spurious variants in combination with discovering many
more truly harmful ones will lead to a net increase in these
numbers. On the basis of our current findings, we predict
that the average individual might eventually be found to
carry >400 damaging variants and >2 disease-causingmber 7, 2012
ones (~5, if we assume that most disease mutations would
be singletons in this data set and apply a simple correction
for incomplete singleton ascertainment), estimates
remarkably consistent with several of the early theoretical
studies.6,7 Now, however, in addition to knowing the
numbers, we also know the identities of at least some of
these damaging and disease-causing variants.
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